{
    "nctId": "NCT04875351",
    "briefTitle": "Breast Cancer Index (BCI) Registry",
    "officialTitle": "Breast Cancer Index (BCI) Registry",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 3465,
    "primaryOutcomeMeasure": "To determine BCI test performance by evaluating the long-term outcome of BCI risk groups over the follow-up period.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Early stage (I, II or III) female breast cancer patients, who have completed 4-7 years of primary adjuvant endocrine therapy\n* Patient was diagnosed with invasive breast carcinoma (ductal, lobular, or mixed ductal/lobular).\n* The primary tumor was hormone receptor positive (HR+), i.e. estrogen receptor-positive and/or progesterone receptor-positive.\n* The primary tumor was HER2 negative or positive and node-negative or node-positive with 1-3 positive lymph nodes.\n* Subject has pre-treatment breast tumor tissue \\[formalin fixed and paraffin embedded (FFPE)\\] from a previous breast-conserving surgery, mastectomy or core needle biopsy available for testing by the Sponsor.\n\nExclusion Criteria:\n\n* Patient has distant metastatic disease (M1).\n* Patient was diagnosed with metaplastic breast cancer, carcinosarcoma, sarcoma, neuroendocrine carcinoma, adenoid cystic carcinoma, or phyllodes tumor.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}